130 related articles for article (PubMed ID: 19731817)
1. [Mirtazapine--pharmacologic action and clinical advantages].
Rihmer Z; Purebl G
Neuropsychopharmacol Hung; 2009 Mar; 11(1):35-40. PubMed ID: 19731817
[TBL] [Abstract][Full Text] [Related]
2. Mirtazapine: pharmacology in relation to adverse effects.
Nutt D
Acta Psychiatr Scand Suppl; 1997; 391():31-7. PubMed ID: 9265949
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study.
Winokur A; Sateia MJ; Hayes JB; Bayles-Dazet W; MacDonald MM; Gary KA
Biol Psychiatry; 2000 Jul; 48(1):75-8. PubMed ID: 10913511
[TBL] [Abstract][Full Text] [Related]
4. Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine.
Shen J; Chung SA; Kayumov L; Moller H; Hossain N; Wang X; Deb P; Sun F; Huang X; Novak M; Appleton D; Shapiro CM
Can J Psychiatry; 2006 Jan; 51(1):27-34. PubMed ID: 16491981
[TBL] [Abstract][Full Text] [Related]
5. Dual action antidepressants and some important considerations.
Gupta RK; Tiller JW; Burrows GD
Aust N Z J Psychiatry; 2003 Apr; 37(2):190-5. PubMed ID: 12656958
[TBL] [Abstract][Full Text] [Related]
6. Intravenous mirtazapine in the treatment of depressed inpatients.
Konstantinidis A; Stastny J; Ptak-Butta J; Hilger E; Winkler D; Barnas C; Neumeister A; Kasper S
Eur Neuropsychopharmacol; 2002 Feb; 12(1):57-60. PubMed ID: 11788241
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and safety aspects of mirtazapine.
Nutt DJ
Hum Psychopharmacol; 2002 Jun; 17 Suppl 1():S37-41. PubMed ID: 12404669
[TBL] [Abstract][Full Text] [Related]
8. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
Winokur A; DeMartinis NA; McNally DP; Gary EM; Cormier JL; Gary KA
J Clin Psychiatry; 2003 Oct; 64(10):1224-9. PubMed ID: 14658972
[TBL] [Abstract][Full Text] [Related]
9. Effects of mirtazapine on sleep polygraphic variables in major depression.
Schittecatte M; Dumont F; Machowski R; Cornil C; Lavergne F; Wilmotte J
Neuropsychobiology; 2002; 46(4):197-201. PubMed ID: 12566938
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
11. [Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
Osváth P
Neuropsychopharmacol Hung; 2013 Sep; 15(3):147-55. PubMed ID: 24108179
[TBL] [Abstract][Full Text] [Related]
12. [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].
Wichniak A; Wierzbicka A
Pol Merkur Lekarski; 2011 Jul; 31(181):65-70. PubMed ID: 21870714
[TBL] [Abstract][Full Text] [Related]
13. Mirtazapine: a newer antidepressant.
Hartmann PM
Am Fam Physician; 1999 Jan; 59(1):159-61. PubMed ID: 9917581
[TBL] [Abstract][Full Text] [Related]
14. Real-world, open-label study to evaluate the effectiveness of mirtazapine on sleep quality in outpatients with major depressive disorder.
Wang D; Li Z; Li L; Hao W
Asia Pac Psychiatry; 2014 Jun; 6(2):152-60. PubMed ID: 23857869
[TBL] [Abstract][Full Text] [Related]
15. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor.
Kakui N; Yokoyama F; Yamauchi M; Kitamura K; Imanishi T; Inoue T; Koyama T
Pharmacol Biochem Behav; 2009 May; 92(3):393-8. PubMed ID: 19167420
[TBL] [Abstract][Full Text] [Related]
16. [Interference in the serotoninergic and noradrenergic system. Faster out of depression].
MMW Fortschr Med; 2001 Nov; 143(44):57. PubMed ID: 11732403
[No Abstract] [Full Text] [Related]
17. Improved insulin sensitivity in 51 nondiabetic depressed inpatients remitting during antidepressive treatment with mirtazapine and venlafaxine.
Weber-Hamann B; Gilles M; Schilling C; Onken V; Frankhauser P; Kopf D; Lederbogen F; Deuschle M
J Clin Psychopharmacol; 2008 Oct; 28(5):581-4. PubMed ID: 18794665
[No Abstract] [Full Text] [Related]
18. Mirtazapine, but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of alpha(2)-adrenergic receptors in depression.
Schittecatte M; Dumont F; Machowski R; Fontaine E; Cornil C; Mendlewicz J; Wilmotte J
Psychiatry Res; 2002 Jan; 109(1):1-8. PubMed ID: 11850045
[TBL] [Abstract][Full Text] [Related]
19. Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.
Lee HY; Kang RH; Paik JW; Jeong YJ; Chang HS; Han SW; Lee MS
Brain Res; 2009 Mar; 1262():1-6. PubMed ID: 19401164
[TBL] [Abstract][Full Text] [Related]
20. [Motivational therapy can fail here. Sleep disorders in depressions].
MMW Fortschr Med; 2004 Aug; 146(33-34):52. PubMed ID: 15526634
[No Abstract] [Full Text] [Related]
[Next] [New Search]
